Navigation Links
Cardiac Science Sets Date for Fourth Quarter, Year-End Results Release and Conference Call
Date:3/3/2010

BOTHELL, Wash., March 3 /PRNewswire-FirstCall/ Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, announced today that it will release its fourth quarter 2009 financial results on Thursday, March 11, 2010 after market close. The Company has scheduled a conference call with analysts and investors for 4:30 p.m. Eastern Time. During the call, Cardiac Science management will discuss the financial results for the fourth quarter as well as the current business outlook.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

To access the conference call, please dial 888.549.7880 and reference conference ID 4252130. Callers outside the U.S. can dial 480.629.9868. The call will also be webcast live at www.cardiacscience.com. An audio replay of the call will be available for 7 days following the call at 800.406.7325 for U.S. callers or 303.590.3030 for those calling from outside the U.S. The password required to access the replay is 4252130#. An archived webcast will also be available at www.cardiacscience.com for 90 days.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, and YouTube at http://budurl.com/CSonYT.


     For more information,
     Company Contact:                  Investor Contact:
     Mike Matysik                      Matt Clawson
     Cardiac Science Corporation       Allen & Caron
     Senior Vice President and CFO     949.474.4300
     425.402.2009                      matt@allencaron.com

     Media Contact:
     Christopher Gale
     EVC Group Inc.
     646.201.5431
     203.570.4681
     cgale@evcgroup.com


    LOGO: http://www.cardiacscience.com/images/main_logo.gif

CSCX-F

SOURCE Cardiac Science Corporation

Back to top

RELATED LINKS
http://www.cardiacscience.com

'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. New cardiac CT technology drastically reduces patient radiation exposure
2. Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
3. Herbal Remedies Can Cause Cardiac Problems
4. Sudden Cardiac Arrest Foundation Launches First Virtual Affiliate
5. Study Questions FDA Approvals of Cardiac Devices
6. With Cardiac Rehab, More Is Better: Study
7. Study finds gender gap persists in cardiac care
8. Cooling may benefit children after cardiac arrest
9. Inhibition of GRK2 is protective against acute cardiac stress injuries
10. Resuscitation and Survival Rates from Out-of-Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol
11. Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... West Hempstead, NY (PRWEB) , ... June 20, ... ... most experienced in the security systems industry has been selected as the partner ... , Amtrak is a passenger railroad service that provides medium- and long-distance intercity ...
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, ... like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. ... and expertise in healthcare will provide invaluable direction for the company,” says Andrew ...
(Date:6/20/2017)... ... , ... The law firm of Momkus McCluskey Roberts LLC congratulates ... DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the leadership role ... Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology: